Crisnatol
Chemical compound
- none
- 2-(Chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol
- 96389-68-3 Y
- 57062
- 51449 Y
- 2J71UR51UE
- DTXSID10242217
- Interactive image
- CC(CO)(CO)NCc1cc2c3ccccc3ccc2c4c1cccc4
InChI
- InChI=InChI=1S/C23H23NO2/c1-23(14-25,15-26)24-13-17-12-22-18-7-3-2-6-16(18)10-11-21(22)20-9-5-4-8-19(17)20/h2-12,24-26H,13-15H2,1H3 Y
- Key:SBRXTSOCZITGQG-UHFFFAOYSA-N Y
Crisnatol (BW-A770U) is an experimental anticancer agent.[1] A Phase I clinical trial was published in 1999.[2]
References
- v
- t
- e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e